Early this week, clinical-stage biopharmaceutical company Enterome announced that the first patient was dosed in a Phase 1/2 clinical trial. The SPENCER trial will evaluate EO2401 as a potential treatment…
According to a story from BioSpace, the biopharmaceutical company POXEL SA has recently announced that it has commenced with a phase 2 dose ranging clinical trial which will test the…
According to a story from Pharmaceutical Business Review, the pharmaceutical company Bayer has recently announced encouraging findings from its phase 4 clinical study. This trial was testing the drug riociguat…
Between August 29 and September 1, researchers joined in at ESC 2020 - The Digital Experience, developed and organized by the European Society of Cardiology (ESC). During this online conference,…
Researchers in Canada have just released positive results from their heterozygous familial hypercholesterolemia (HeFH) clinical trial. This investigation was examining the effect of Repatha on teenagers with the condition. The trial…
by Caitlin Seida from In The Cloud Copy Isolation as a result of COVID-19 precautions is necessary but can take its toll on your physical, mental, emotional, and spiritual well-being.…
Business Insider recently interviewed Marissa Oliver, a resident of New York City, who told us about the problems she has encountered during her recovery from COVID-19. Marissa, an arts manager,…
As reported in Newswise; this week, researchers across the world have been given access to a new guide that could fundamentally better the outcomes of people living with chronic kidney…
© Copyright 2024 Patient Worthy
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
